Redcliffe Labs Achieves 20% Revenue Growth in FY25

Redcliffe Labs, a prominent diagnostics platform, has achieved a remarkable 20% increase in operating revenue, rising to Rs 419 crore in FY25 from Rs 350 crore in FY24, according to a company press release. The Gurugram-headquartered firm has also made significant strides in reducing its EBITDA losses, decreasing from -38% to -21% in the same timeframe.

Redcliffe Labs: A National Presence

Founded by Aditya Kandoi, Redcliffe Labs operates an extensive network with over 80 labs, claiming to have the most comprehensive home sample collection service in India. Diagnostic services accounted for over 95% of the company’s revenue in FY25, while the remaining income came from product sales and other operational sources.

Focus on Expansion and Underserved Regions

The company reported diagnosing more than 2.5 million cases in the last fiscal year and is committed to expanding into underserved regions, with over 70% of its testing volumes sourced from Tier II cities and beyond.

Profitability and Future Goals

In terms of profitability, Redcliffe recorded a gross margin of 70% in FY25 and is striving to increase this to 74% in FY26. The company has also established a revenue goal of Rs 560 crore for the current fiscal year through both organic growth and strategic acquisitions.

Kandoi highlighted the company’s mission by stating that Redcliffe aims to transform lives and make diagnostics a primary solution for millions who previously lacked access to these services. The firm plans to expand its footprint to over 300 cities with 150 labs by FY28.

Investment and Competition

According to various sources from startup data platforms, Redcliffe has successfully raised $113 million to date, including a notable $42 million Series C funding round spearheaded by LeapFrog. This growth also includes the acquisition of Bengaluru-based Celara Diagnostics in a deal valued at $7 million.

In a competitive landscape, Redcliffe Labs faces rivals such as Thyrocare, owned by PharmEasy, which reported Rs 687 crore in revenue and Rs 91 crore in profit for FY25; Tata 1mg, which posted a topline of Rs 1,968 crore in FY24; and Healthians, which recorded revenue of Rs 250 crore in FY24.